JP2017509323A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509323A5
JP2017509323A5 JP2016549449A JP2016549449A JP2017509323A5 JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5 JP 2016549449 A JP2016549449 A JP 2016549449A JP 2016549449 A JP2016549449 A JP 2016549449A JP 2017509323 A5 JP2017509323 A5 JP 2017509323A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
binding molecule
molecule according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016549449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017509323A (ja
JP6687526B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/052098 external-priority patent/WO2015114150A1/en
Publication of JP2017509323A publication Critical patent/JP2017509323A/ja
Publication of JP2017509323A5 publication Critical patent/JP2017509323A5/ja
Application granted granted Critical
Publication of JP6687526B2 publication Critical patent/JP6687526B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016549449A 2014-02-02 2015-02-02 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質 Active JP6687526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934828P 2014-02-02 2014-02-02
US61/934,828 2014-02-02
PCT/EP2015/052098 WO2015114150A1 (en) 2014-02-02 2015-02-02 Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020065513A Division JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Publications (3)

Publication Number Publication Date
JP2017509323A JP2017509323A (ja) 2017-04-06
JP2017509323A5 true JP2017509323A5 (enExample) 2018-03-08
JP6687526B2 JP6687526B2 (ja) 2020-04-22

Family

ID=52440681

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016549449A Active JP6687526B2 (ja) 2014-02-02 2015-02-02 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2020065513A Active JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2022077858A Active JP7520070B2 (ja) 2014-02-02 2022-05-11 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2024109298A Pending JP2024133644A (ja) 2014-02-02 2024-07-08 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020065513A Active JP7074792B2 (ja) 2014-02-02 2020-04-01 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2022077858A Active JP7520070B2 (ja) 2014-02-02 2022-05-11 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質
JP2024109298A Pending JP2024133644A (ja) 2014-02-02 2024-07-08 NGFアンタゴニストドメインおよびTNFαアンタゴニストドメインから構成されるキメラタンパク質

Country Status (21)

Country Link
US (5) US9884911B2 (enExample)
EP (2) EP3696193A1 (enExample)
JP (4) JP6687526B2 (enExample)
KR (1) KR102489452B1 (enExample)
CN (2) CN106459190A (enExample)
AU (3) AU2015212787B2 (enExample)
CA (1) CA2938066C (enExample)
CY (1) CY1123248T1 (enExample)
DK (1) DK3099713T3 (enExample)
ES (1) ES2784238T3 (enExample)
HR (1) HRP20200477T1 (enExample)
HU (1) HUE048478T2 (enExample)
LT (1) LT3099713T (enExample)
MX (1) MX382763B (enExample)
PL (1) PL3099713T3 (enExample)
PT (1) PT3099713T (enExample)
RS (1) RS60156B1 (enExample)
RU (1) RU2678810C2 (enExample)
SI (1) SI3099713T1 (enExample)
SM (1) SMT202000182T1 (enExample)
WO (1) WO2015114150A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102489452B1 (ko) 2014-02-02 2023-01-16 메디뮨 리미티드 Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질
US9862760B2 (en) * 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
US11572395B2 (en) 2017-09-21 2023-02-07 Merck Patent Gmbh Fusion protein comprising an FGF-18 moiety
WO2021142573A1 (zh) * 2020-01-13 2021-07-22 丁邦 一种融合蛋白及其制法和用途
US20240026036A1 (en) * 2020-09-28 2024-01-25 Medimmune Limited Compounds and methods for treating pain
CN114574444B (zh) * 2020-12-01 2024-05-03 达达生物技术(北京)有限公司 自体纤维母细胞在制备抗类风湿关节炎药物中的应用
TWI821881B (zh) * 2021-01-29 2023-11-11 醫研生物科技有限公司 腫瘤壞死因子α重組抗體及其用途
CN116179667A (zh) * 2022-09-21 2023-05-30 福建中妆技术研究有限公司 基于斑马鱼模型中trpv1信号通路筛选皮肤疼痛舒缓原料的试剂盒及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681718A (en) 1986-03-14 1997-10-28 Celltech Limited Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
DE19926068C1 (de) * 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
NZ529612A (en) 2001-05-30 2006-03-31 Genentech Inc Anti-NGF antibodies for the treatment of various disorders
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
PT1556083E (pt) 2002-10-08 2011-03-17 Rinat Neuroscience Corp Métodos para tratar a dor pós-cirúrgica pela administração de um anticorpo contra o factor de crescimento nervoso e composições que contêm o mesmo
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
WO2005075514A2 (en) 2004-03-10 2005-08-18 Lonza Ltd. Method for producing antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
PT1846451E (pt) 2005-01-24 2013-08-28 Elan Pharma Int Ltd Membros de ligação específica para ngf
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
CN101802197A (zh) * 2007-05-14 2010-08-11 比奥根艾迪克Ma公司 单链FC(ScFc)区、包含其的结合多肽及与其相关的方法
US8093364B2 (en) 2008-01-18 2012-01-10 Bio-Rad Laboratories, Inc. Enhanced purification of antibodies and antibody fragments by apatite chromatography
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2010014574A (es) * 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
JP2011016676A (ja) * 2009-07-07 2011-01-27 Sumitomo Electric Ind Ltd 窒化物半導体基板の製造方法
BR112012008833A2 (pt) * 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
JP2013512674A (ja) * 2009-12-02 2013-04-18 アクセルロン ファーマ, インコーポレイテッド Fc融合タンパク質の血清半減期を増加させるための組成物および方法
SG184473A1 (en) * 2010-04-07 2012-11-29 Abbvie Inc Tnf-alpha binding proteins
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
AU2012336069A1 (en) 2011-11-07 2014-05-22 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
WO2013101972A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2014106001A2 (en) * 2012-12-28 2014-07-03 Abbvie, Inc. Dual specific binding proteins having a receptor sequence
BR112015023557A2 (pt) 2013-03-15 2017-10-24 Abbvie Inc proteínas de ligações dual específicas direcionadas contra tnfa
KR102489452B1 (ko) * 2014-02-02 2023-01-16 메디뮨 리미티드 Ngf 길항제 도메인 및 tnfa 길항제 도메인으로 구성된 키메라 단백질
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US20210009671A1 (en) 2019-05-10 2021-01-14 Medimmune Limited Compounds and methods for treating pain

Similar Documents

Publication Publication Date Title
JP2017509323A5 (enExample)
CN111518214B (zh) 靶向cldn18.2的双特异性抗体及其制备方法和应用
CA2903595C (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
CN110305210B (zh) 新型抗体分子、其制备方法及其用途
CN107922486B (zh) 异源二聚体多特异性抗体形式
JP2013515508A5 (enExample)
US20170306018A1 (en) Bispecific antibodies against cd3epsilon and ror1
HRP20241775T1 (hr) Bispecifična protutijela koja se specifično vežu na pd1 i lag3
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2017504578A5 (enExample)
JP2010502183A5 (enExample)
JP2014158485A5 (enExample)
JP2017522891A5 (enExample)
IL295295A (en) Antibodies against fcrl5 and methods of their use
JP2005518789A5 (enExample)
JP2017520575A5 (enExample)
US20210054021A1 (en) Stabilized immunoglobulin domains
JP2019502694A5 (enExample)
JP2020524510A5 (enExample)
JP2020515277A5 (enExample)
JP2020524661A5 (enExample)
JP2019535315A5 (enExample)
JP2020502233A5 (enExample)
JP2021512159A5 (enExample)
JP2017534296A5 (enExample)